Pemafibrate is associated with greater reductions in MDA-LDL and small dense LDL fractions with exploratory PBMC gene-expression changes: a prespecified subanalysis of the PARADISE in Kagoshima study.
- DOI
- 10.3389/fcdhc.2026.1850470
- Published
- 2026
- Container
- Frontiers in clinical diabetes and healthcare
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3389/fcdhc.2026.1850470,
title = {Pemafibrate is associated with greater reductions in MDA-LDL and small dense LDL fractions with exploratory PBMC gene-expression changes: a prespecified subanalysis of the PARADISE in Kagoshima study.},
author = {Kubo T and Deguchi T and Matsuzaki K and Shinnakasu A and Kawade S and Arimura A and Hashiguchi H and Ogiso K and Kamada T and Kurano M and Morino K and Nishio Y},
year = {2026},
journal = {Frontiers in clinical diabetes and healthcare},
doi = {10.3389/fcdhc.2026.1850470},
url = {https://doi.org/10.3389/fcdhc.2026.1850470}
}RIS
TY - JOUR TI - Pemafibrate is associated with greater reductions in MDA-LDL and small dense LDL fractions with exploratory PBMC gene-expression changes: a prespecified subanalysis of the PARADISE in Kagoshima study. AU - Kubo T AU - Deguchi T AU - Matsuzaki K AU - Shinnakasu A AU - Kawade S AU - Arimura A AU - Hashiguchi H AU - Ogiso K AU - Kamada T AU - Kurano M AU - Morino K AU - Nishio Y PY - 2026 JO - Frontiers in clinical diabetes and healthcare DO - 10.3389/fcdhc.2026.1850470 UR - https://doi.org/10.3389/fcdhc.2026.1850470 ER -
APA
T, K., T, D., K, M., A, S., S, K., A, A., H, H., K, O., T, K., M, K., K, M., & Y, N. (2026). Pemafibrate is associated with greater reductions in MDA-LDL and small dense LDL fractions with exploratory PBMC gene-expression changes: a prespecified subanalysis of the PARADISE in Kagoshima study.. Frontiers in clinical diabetes and healthcare. https://doi.org/10.3389/fcdhc.2026.1850470
Source records
- pubmed · retrieved 2026-09-26T02:36:03.966Z